Gerresheimer Presents Gx Elite Vials at CPhI Worldwide

Published on: 

The Gx Elite vials are the result of comprehensive optimization measures in the conversion process, which have focused on designing out the risk to create product flaws during production including the removal of all glass-to-glass contact beginning with the tubing material all the way through final packaging.

Gerresheimer will be showcasing its Gx Elite vials at CPhI Worldwide in Frankfurt, Germany from Oct. 24–26 2017. The vials have the same chemical composition of borosilicate glass but the conversion process has been optimized to design out the risk of product flaws during production and remove all glass-to-glass contact beginning with the tubing material all the way through final packaging. As a result, the Gx Elite vials have better quality.

The highly shatter-resistant vials are durable and free of cosmetic defects. They have a robust structure, while their resistance to delamination protects the drug inside. Simple handling and a range of packaging options ensure that Gx Elite vials can be supplied for end-to-end use on various filling lines. For customers, this means lower costs and higher quality.  

Gerresheimer’s tubular glass plants that produce vials work with standardized monitoring, inspection, and packaging technologies, which essentially comprise the Gx G3 and Gx RHOC systems. The inspection systems are developed in house and form part of a close-knit testing system that ensures high precision and quality assurance in line with the latest standards. Complete with five HD cameras, the Gx G3 inspection system ensures that cosmetic defects are identified reliably. The intelligent software detects and classifies the defects in a few fractions of a second, while the Gx RHOC system ensures dimensional quality with three HD matrix cameras on each side and a hypercentric ID camera. 


Injection vials set the benchmark for primary packaging for parenteral drugs. Gerresheimer’s vials come in all sizes and comply with the relevant international standards and pharmacopoeias (EU, USP, JP). The company’s range includes solutions for bioengineered drugs and other specialist pharmaceuticals.

Source: Gerresheimer, Booth D02 in Hall 4.2